MgSO4 Trial: What is the optimal rate of administration
of Magnesium Sulphate for neuroprotection prior to preterm birth.
This trial is currently recruiting.
Magnesium sulphate immediately prior to very preterm birth may reduce the risk
of cerebral palsy (Crowther et al 2004).
Intravenous administration leads to side effects sufficient to stop the medication
in a significant number of women. This trial will examine different rates of
giving the infusion to ensure the optimal dose is given to women but with minimal
side effects.
| Chief Investigators: |
Prof Caroline Crowther, Dr Jodie Dodd. |
| Clinical Trial Coordinator: |
Ms Pat Ashwood |
| Email: |
pat.ashwood@adelaide.edu.au |
Phone:
Fax: |
61 8 8161 7767
61 8 8161 7652 |
| Address: |
ARCH
Discipline of Obstetrics and Gynaecology
The University of Adelaide
Women's and Children's Hospital
King William Road
North Adelaide
South Australia 5006 |
Reference
Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative
Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium
sulfate given for neuroprotection before preterm birth: a randomized controlled
trial. JAMA 2003 Nov26; 290(20):2669-76. (Article)
|
